Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study

By sjmartinez • May 30, 2024

Xie M, Vuko M, Rodriguez-Canales J, Zimmermann J, Schick M, O'Brien C, Paz-Ares L, Goldman JW, Garassino MC, Gay CM, Heymach JV, Jiang H, Barrett JC, Stewart RA, Lai Z, Byers LA, Rudin CM, Shrestha Y. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study. Mol Cancer. 2024 May 30;23(1):115. doi: 10.1186/s12943-024-02014-x. PMID: 38811992; PMCID: PMC11137956.

Tags: Antigen presentation machinery, biomarkers, CTLA-4, Gene Expression Profiling, Hematology/Oncology, Molecular subtyping, PD-L1, Publications, SCLC subtypes, Small-cell lung cancer, T-cell inflamed signature

TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer

Okamoto I, Kuyama S, Girard N, Lu S, Franke F, Li Z, Danchaivijitr P, Han JY, Sun JM, Sugawara S, Pan E, Ren N, Chen[...]

Insurance remains a major source of disparity for patients with testicular cancer: call for advocacy

Starr S, Zhang J, Lin L, Shen J, Gamalong G, Litwin MS, Drakaki A, Chamie K. Insurance remains a major source of disparity for patients[...]

NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3

Wainberg ZA, M O'Reilly E. NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3. Nat Rev Clin Oncol. 2024 Oct 25. doi: 10.1038/s41571-024-00952-5.[...]